Clinical Trial Update: Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluated combination chemotherapy plus bevacizumab for metastatic prostate cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 2 | Status: COMPLETED